Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies

Phase 2

Completed

Conditions: Hematologic Malignancies

Interventions: Procedure: extracorporeal photopheresis
Drug: Pentostatin
Radiation: Total Body Irradiation

First Posted Date: 2006-11-22

Last Posted Date: 2017-01-18

Lead Sponsor: Yale University

Target Recruit Count: 14

Registration Number: NCT00402714

Locations: 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Tufts-New England Medical Center, Boston, Massachusetts, United States
🇺🇸
Methodist Hospital - Texas Transplant Institute, San Antonio, Texas, United States

Expression of Mif Alleles in Individuals With Leishmaniasis

Completed

Conditions: Leishmaniasis

First Posted Date: 2006-11-20

Last Posted Date: 2020-03-30

Lead Sponsor: Yale University

Target Recruit Count: 438

Registration Number: NCT00401349

Locations: 🇨🇴
Centro Internacional de Entrenamiento e Investigaciones Medicas, CIDEIM, Cali, Colombia

Th1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes

Completed

Conditions: Leishmaniasis

First Posted Date: 2006-11-20

Last Posted Date: 2020-03-30

Lead Sponsor: Yale University

Target Recruit Count: 122

Registration Number: NCT00401297

Locations: 🇨🇴
Centro Internacional de Entrenamiento e Investigaciones Medicas, CIDEIM, Cali, Colombia

Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection

Completed

Conditions: Leishmaniasis

First Posted Date: 2006-11-20

Last Posted Date: 2020-03-30

Lead Sponsor: Yale University

Target Recruit Count: 34

Registration Number: NCT00401557

Locations: 🇨🇴
Centro Internacional de Entrenamiento e Investigaciones Medicas, CIDEIM, Cali, Colombia

Recovery Guide Intervention for Recurrent Psychiatric Hospitalization

Not Applicable

Completed

Conditions: Schizophrenia
Schizoaffective Disorder
Bipolar Disorder
Psychotic Depression

Interventions: Behavioral: Recovery Mentor

First Posted Date: 2006-11-16

Last Posted Date: 2009-06-12

Lead Sponsor: Yale University

Target Recruit Count: 71

Registration Number: NCT00400166

Locations: 🇺🇸
Yale-New Haven Psychiatric Hospital, New Haven, Connecticut, United States

HIV Risk Reduction and Drug Abuse Treatment in Iran

Phase 2

Withdrawn

Conditions: Opiate Dependence
HIV Infections

Interventions: Drug: Buprenorphine/Subutex
Drug: Naltrexone
Behavioral: Drug counseling

First Posted Date: 2006-11-10

Last Posted Date: 2020-03-30

Lead Sponsor: Yale University

Registration Number: NCT00398008

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇮🇷
Institute for Cognitive Studies, Tehran, Iran, Islamic Republic of

Why Are Patients With Absence Seizures Absent? A Brain Imaging Study

Completed

Conditions: Childhood Absence Epilepsy

First Posted Date: 2006-10-29

Last Posted Date: 2016-01-26

Lead Sponsor: Yale University

Target Recruit Count: 180

Registration Number: NCT00393666

Locations: 🇺🇸
Yale University School of Medicine, Neurology Department, New Haven, Connecticut, United States

HIV Risk Reduction and Drug Abuse Treatment in Malaysia

Phase 2

Completed

Conditions: Opiate Dependence

First Posted Date: 2006-10-02

Last Posted Date: 2020-03-31

Lead Sponsor: Yale University

Target Recruit Count: 180

Registration Number: NCT00383045

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇲🇾
Substance Abuse Research Center, Muar, Johor, Malaysia

Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes

Phase 2

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: mAb hOKT3gamma1(Ala-Ala), Teplizumab
Drug: Placebo Arm

First Posted Date: 2006-09-20

Last Posted Date: 2021-08-13

Lead Sponsor: Yale University

Target Recruit Count: 63

Registration Number: NCT00378508

Locations: 🇺🇸
University of California at San Francisco, San Francisco, California, United States
🇺🇸
Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
🇺🇸
Barbara Davis Diabetes Center, Aurora, Colorado, United States

and more 1 locations

Treatment of Refractory Schizophrenia With Riluzole

Not Applicable

Completed

Conditions: Schizophrenia
Schizoaffective

Interventions: Drug: Riluzole
Drug: Placebo

First Posted Date: 2006-09-12

Last Posted Date: 2019-12-09

Lead Sponsor: Yale University

Target Recruit Count: 34

Registration Number: NCT00375050

Locations: 🇺🇸
Yale Department of Psychiatry, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy